China announces massive drug safety spend

19 August 2007

The Chinese government has announced a $1.7 billion upgrade of the country's food and drug safety monitoring capacity, as part of a major effort to bolster China's recently-tarnished reputation (Marketletters passim). A spokesman for the State Food and Drug Administration told a press conference in Beijing that the funds would be directed at infrastructure improvements over the next three-to-five years, Drug Researcher.com reported.

The Shanghai Daily reported specific details of the spending, including: a new headquarters for the National Institute for the Control of Pharmaceutical and Biological Products; the refurbishment and modernization of 16 drug control centers; and an improved monitoring system for adverse events involving drugs.

With recent problems being investigated by the US Food and Drug Administration, not only in the USA but also in Panama, as well as noting the importance of the US market for Chinese exports, closer ties are being urged between Chinese regulators and their US counterparts. The US federal government recently issued a request for speedier cooperation in the formulation and enforcement of safety standards for food and drugs (Marketletter August 6).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight